GSK-Vir drug works against all Omicron variants - study

GlaxoSmithKline and Vir Biotechnology on Tuesday said their antibody Covid-19 treatment was effective against all mutations of the Omicron variant, according to early-stage studies.

The preclinical data showed the sotrovimab treatment was effective against the 37 known mutations of the Omicron variant, GSK said in a statement.

“These pre-clinical data demonstrate the potential for our monoclonal antibody to be effective against the latest variant, Omicron, plus all other variants of concern defined to date by the WHO, and we look forward to discussing these results with regulatory authorities around the world,” it added.

VIR CEO said he was confident that sotrovimab “will continue to provide significant benefit for the early treatment of patients hoping to avoid the most severe consequences of Covid-19".